

REMARKS

Claims 1, 2, 4, and 26-34 are pending in this application. Claims 1 and 28 are additionally amended by this Amendment. Support for amended claims 1 and 28 can be found throughout the specification, and in particular, at least on p. 17, lines 10-25, p. 27-27, and p. 34, lines 7-11. A marked up version of claims showing changes made is attached herewith. It is Applicants' express position that the change in the claim language merely more clearly defines the end-point result of the claimed methods, and does not in any way restrict the scope of the claims or the range of equivalents.

Pursuant to a duty of disclosure under C.F.R. § 1.97, Applicants inform the Examiner of a copending Application No. 09/431,979, filed on October 29, 1999, by the above-identified Applicants.

Please grant any extensions of time required to enter this amendment and charge any additional required fees to deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 27, 2002

By: Leslie A. McDonell
Leslie A. McDonell
Reg. No. 34,872

Appendix

1. (Twice amended) A method of inhibiting ~~the differentiation of an activated~~ cytotoxic activity of a T cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a P-selecting glycoprotein ligand (PSGL) antagonist.
2. The method of claim 1, wherein said P-selectin glycoprotein ligand (PSGL) antagonist is selected from the group consisting of a soluble form of PSGL, an antibody directed to PSGL, an antibody directed to sLe_x, an antibody directed to sulfated tyrosine, sLe_x, mimetics which inhibit sLe_x binding and a small molecule inhibitor of PSGL binding.
4. The method of claim 2, wherein said PSGL antagonist is an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof,
26. The method of claim 4, wherein said antibody is a monoclonal antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.
27. The method of claim 4, wherein said antibody is administered in a pharmaceutically acceptable formulation.
28. (Amended) A method for treating or ameliorating, ~~in a subject,~~ a disease or condition resulting from ~~differentiation of activated T-cells into cytotoxic lymphocytes~~ a CTL response comprising administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.
29. The method of claim 28, wherein said disease or condition is an autoimmune condition.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

30. The method of claim 28, wherein said disease or condition is an allergic reaction.
31. The method of claim 28, wherein said disease or condition is asthma.
32. The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof.
33. The method of claim 28, wherein said subject is a mammalian subject.
34. The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000